Announcements
- Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
- Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
- Medigene to Present at Upcoming Conferences
- Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
- Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
- Medigene AG reports Financial Results and Business Update for Q1 2024
- Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
- Medigene to Present at Upcoming Scientific Conferences
- Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
- Medigene AG Secures European Patent for its iM-TCR Technology
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 8.76 |
Average volume | -- |
---|---|
Shares outstanding | 29.48m |
Free float | 28.61m |
P/E (TTM) | -- |
Market cap | 41.41m EUR |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Jun 17 2019.
More ▼